Rapamycin Liposomes Targeted to Lymph Nodes Inhibit Dendritic Cell Maturation for the Treatment of Transplant Rejection
Wuqi Zhou,Yishu Song,Luyang Yi,Xueke Li,Mengdan Ding,Junmin Zhang,Yihui Wang,Wenyuan Wang,Lufang Wang,Mengrong He,Qiaofeng Jin,Tang Gao,Mingxing Xie,Li Zhang
DOI: https://doi.org/10.1002/ppsc.202400030
IF: 3.467
2024-06-13
Particle & Particle Systems Characterization
Abstract:A kind of lipid nanoparticle containing rapamycin (LNP@rapa) is prepared. Following subcutaneous injection, LNP@rapa gains entry into lymph nodes via phagocytosis by immature dendritic cell (imDCs). Rapamycin's action involves the inhibition of imDC maturation by restraining the mammalian target of rapamycin (mTOR) pathway, culminating in costimulation blockade with T cells, and thus mitigating transplant rejection. The activation of naive T cells by mature dendritic cells (DCs) presenting allograft antigens marks a pivotal stage in triggering transplant rejection. A critical intervention in this process involves the administration of rapamycin, which disrupts the mTOR signaling pathway, thereby impeding DC maturation. Nevertheless, systemic administration of rapamycin faces challenges due to its limited bioavailability, non‐specific targeting, and notable side effects. To address these limitations, LNP@rapa (liposome‐encapsulated rapamycin) is developed, administered via subcutaneous injection. This formulation selectively targets lymph nodes, inhibiting DC maturation within these nodes and mitigating transplant rejection. This study validates the in vivo efficacy of LNP@rapa, demonstrating its ability to hinder DC maturation, reduce inflammatory cytokine secretion, and significantly prolong graft survival in two distinct mouse transplantation models. This study introduces an innovative strategy targeting lymph nodes to impede DC maturation, offering a promising approach to address transplant rejection.
materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology